Zynerba Pharmaceuticals (ZYNE) Financials

$1.30

$0.00 (0.00%)

As on 13-Oct-2023 09:30EDT

Market cap

$70 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	--	--	--	0.09
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	0.09
Operating Expenses	38.79	35.25	36.77	52.06	34.32	40.48
Operating Profit (EBIT)	-38.79	-35.25	-36.77	-52.06	-34.32	-40.40
Other Income	-0.07	--	--	0.48	-0.15	-0.47
Profit before Tax	-37.58	-35.04	-37.31	-51.34	-32.94	-39.91
Provision for Tax	-0.93	-0.22	0.29	-0.93	-1.51	0.49
Profit after Tax (Net Income)	-37.01	-34.82	-37.60	-50.40	-31.43	-39.91
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-19.45	--	-37.31	-51.34	-32.94	-39.91

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	29.02	46.23	70.91	60.14	75.60	57.60
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	0.12	0.35	2.63	0.11	--
Current Liabilities	11.46	9.17	9.90	13.91	12.06	9.73
Total Liabilities	51.93	55.52	81.17	74.06	87.76	67.33

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	1.18	0.75	0.95	0.69	0.71	0.37
Current Assets	39.29	54.78	80.22	73.37	87.06	66.96
Total Assets	51.93	55.52	81.17	74.06	87.76	67.33
Total Debt*	0.22	0.33	0.56	0.11	0.35	--
Net Current Assets	27.84	45.60	70.32	59.45	75.00	57.23

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-23.03	-33.46	-41.31	-34.82	-32.40
Cash Flow from Investing Activities	--	--	-0.05	-0.45	-0.13	-0.29
Cash from Financing Activities	--	6.01	42.16	30.85	45.25	29.94
Net Cash Inflow / Outflow	--	--	--	-10.91	10.30	-2.75

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-0.79	-0.77	-0.93	-1.72	-1.36	-2.27
Cash EPS ($)	--	-0.77	-0.93	-1.71	-1.35	-2.26
Adjusted Book Value ($)	--	1.02	1.76	2.05	3.26	3.27
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.51	-0.83	-1.41	-1.50	-1.84
Free Cash Flow per Share ($)	--	-0.51	-0.83	-1.43	-1.51	-1.86

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-59.00	-57.09	-74.01	-47.07	-67.33
ROE (%)	-98.36	-59.45	-57.38	-74.27	-47.20	-67.33
ROA (%)	-57.62	-50.95	-48.45	-62.30	-40.54	-58.53
EBIT Margin (%)	--	--	--	--	--	-46,538.06
Net Margin (%)	49,625.92	--	--	-10,463.38	21,542.91	10,268.71
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	--	--	-1.00	10.86
EBIT Growth (%)	-5.13	4.13	29.37	-51.70	14.25	-20.52
Net Profit Growth (%)	2.64	7.39	25.40	-60.35	21.24	-24.67
EPS Growth (%)	16.03	0.17	0.46	-0.27	0.40	0.05
Book Value Growth (%)	-58.14	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-0.69	-3.08	-1.92	-4.46	-1.31
Price / Book Value	0.54	0.52	1.63	1.61	1.85	0.91
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.78	0.76	-1.34	-0.72	-2.06	0.19
Close Price ($)	0.33	0.53	2.88	3.30	6.04	2.97
High Price ($)	1.39	3.09	9.00	7.45	16.47	14.45
Low Price ($)	0.30	0.49	2.84	2.55	2.93	2.75
Market Cap ($ Cr)	70.12	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	0.01	0.01	0.00	0.00	--
Short term debt to equity ratio	0.01	0.00	0.00	0.00	0.00	--
Current Ratio	3.43	5.97	8.10	5.27	7.22	6.88
Quick Ratio	3.31	--	--	--	--	--
Interest Coverage	-25.05	-163.40	-68.27	--	--	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	4,005.37
Asset Turnover	--	--	--	--	--	0.00
Receivable days	--	--	--	--	--	15,774.18
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.